The present invention is generally directed to HER-2/neu fusion proteins,nucleic acid molecules encoding HER-2/neu fusion proteins, viral vectorsexpressing HER-2/neu fusion proteins, and pharmaceutical compositions(e.g.vaccines) comprising the HER-2/neu fusion proteins and/or nucleic acidmolecules encoding the HER-2/neu fusion proteins. The present invention isalso directed to methods of treating or preventing cancer by eliciting orenhancing an immune response to the HER-2/neu protein, including for uses inthe treatment of malignancies associated with the HER-2/neu oncogene.
